Navigation Links
DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
Date:1/10/2012

GAITHERSBURG, Md., Jan. 10, 2012 /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) a privately held specialty pharmaceutical company focused exclusively in the HIV-1 therapeutic space, announced today a collaborative agreement between DFH and the National Cancer Institute (NCI) to further the development of the next generation of HIV maturation inhibitor drugs. Maturation inhibitors are a novel class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with the maturation of the HIV-1 virus.

The collaboration will involve extending successful efforts by DFH Pharma to identify drug candidates with potent activity against all HIV strains, including those that proved resistant to the first-in-class maturation inhibitor, bevirimat. DFH scientists have identified a series of 2nd generation maturation inhibitors with the broad anti-viral activity profile necessary for successful HIV drug development. The NCI investigators will evaluate the activity of these compounds against HIV strains associated with reduced bevirimat activity. The most potent of these compounds will be selected for further pre-clinical testing with a goal of initiating human clinical trials with one or more candidate molecules in the near future.

Dr. Eric Freed, an internationally recognized leader in the field of HIV assembly and release, will head the NCI group. Dr. Freed has worked in the maturation inhibition area since the early 2000's when his group collaborated with Panacos Pharmaceuticals in the discovery and characterization of the maturation inhibitor class of HIV drugs. "We are very excited to be working with Dr. Freed and his NCI colleagues in developing this new class of drugs to treat HIV infection"' said Carl Wild, Ph.D., President and CEO. Dr. Wild continued, "The NCI collaboration will allow DFH to build on its recent success in identifying broadly active maturation inhibitor drug can
'/>"/>

SOURCE DFH Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
2. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
3. Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
4. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
5. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
6. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... In contrast to traditional LED lights where ... Valoya uses proprietary LED technology to incorporate their spectra ... which is critical in low proximity installations. The Valoya ... its lifetime which is up to four times longer ... investment cost was clearly higher when compared to traditional ...
(Date:12/19/2014)... MILLBROOK, N.Y. , Dec. 18, 2014 Egenix, ... has been elected Chairman of the Board, to succeed ... President and CEO, but will continue as a member of ... that he has added to the company over almost twenty ... The Board of Directors has established a Search ...
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... for Removal of Clinical Hold, BERKELEY HEIGHTS, ... GNTA) announced that the Company has,received notice of ... Office for its pipeline product, tesetaxel, a leading ... for the tesetaxel drug,substance and to processes for ...
... Targets, COPENHAGEN, June 10 Nuevolution A/S ... (Nasdaq: LXRX ) aimed,at the discovery of ... targets., Under the terms of the alliance, ... to identify novel small molecule,lead compounds against a ...
... June 9 Boston Scientific,Corporation (NYSE: BSX ... it has revised its Rating Outlook on the ... Company,s long-term credit rating of,BB+., Fitch said ... Boston,Scientific is making toward stabilizing its drug-eluting stent ...
Cached Biology Technology:Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 4Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 2Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals 3Boston Scientific Welcomes Revised Outlook From Fitch Ratings 2Boston Scientific Welcomes Revised Outlook From Fitch Ratings 3
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... a mathematical model of the mechanism birds use to ... feather structures involve the coordination of at least two ... "Understanding these mechanisms of feather growth gives a whole ... Richard Prum, senior author on the study. Prum is ...
... Conservation Union reported an unprecedented decline in biodiversity, with ... most species is loss of habitat. And as habitat ... accurately predict the population dynamics and extinction risk of ... new study, John Drake tests models traditionally used to ...
... cause of hospital-acquired infections can persist for days ... healthcare settings, including bed linens, computer keyboard covers ... at the 105th General Meeting of the American ... is a major cause of hospital-acquired infections in ...
Cached Biology News:Simple explanation for complex pattern of feather development 2Traditional models underestimate extinction rates 2
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... Note: Assays in Tris buffer, pH 10.2 ... glycine buffer system. Assays in diethanolamine buffer, ... of the glycine buffer system. Protein determined ... Tris-citrate buffer salts Preparation Unit Definition: One ...
... a wide variety of solvent vapors that can contaminate ... (GCF400) allows for the collection of liquid into a ... minimizes waiting period., Ultra low -104 o ... , Digital Display of temperature ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
Biology Products: